The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials

SD Anker, S Agewall, M Borggrefe… - European heart …, 2014 - academic.oup.com
Abstract Patient-reported outcomes (PROs), such as symptoms, health-related quality of life
(HRQOL), or patient perceived health status, are reported directly by the patient and are …

Implant and midterm outcomes of the subcutaneous implantable cardioverter-defibrillator registry: the EFFORTLESS study

L Boersma, C Barr, R Knops, D Theuns… - Journal of the American …, 2017 - jacc.org
Background: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was
developed to defibrillate ventricular arrhythmias, avoiding drawbacks of transvenous leads …

Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry

PD Lambiase, C Barr, DAMJ Theuns… - European heart …, 2014 - academic.oup.com
Aims The totally subcutaneous implantable-defibrillator (S-ICD) is a new alternative to the
conventional transvenous ICD system to minimize intravascular lead complications. There …

Safety and efficacy of the subcutaneous implantable defibrillator

GF Lewis, MR Gold - Journal of the American College of Cardiology, 2016 - jacc.org
Multiple randomized, multicenter trials have established the role of the implantable
cardioverter-defibrillator (ICD) in the treatment and prevention of sudden cardiac death …

Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study

PD Lambiase, DA Theuns, F Murgatroyd… - European Heart …, 2022 - academic.oup.com
Aims To report 5-year outcomes of EFFORTLESS registry patients with early generation
subcutaneous implantable cardioverter-defibrillator (S-ICD) devices. Methods and results …

Inappropriate shocks in the subcutaneous ICD: incidence, predictors and management

LRAO Nordkamp, TF Brouwer, C Barr… - International journal of …, 2015 - Elsevier
Background The entirely subcutaneous implantable cardioverter-defibrillator (S-ICD)
eliminates the need for transvenous leads, and therefore has the potential to improve lead …

Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management

KM Kooiman, RE Knops, LO Nordkamp, AAM Wilde… - Heart Rhythm, 2014 - Elsevier
Background Inappropriate shocks (IASs) complicate implantable cardioverter-defibrillator
(ICD) therapy. The management of IASs in patients with a subcutaneous ICD (S-ICD) differs …

Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts

PD Lambiase, MR Gold, M Hood, L Boersma… - Heart Rhythm, 2016 - Elsevier
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) is a potential
alternative to transvenous systems in hypertrophic cardiomyopathy (HCM) where lead …

[HTML][HTML] Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction

L Boersma, MC Burke, P Neuzil, P Lambiase… - Heart Rhythm, 2016 - Elsevier
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) provides an
alternative to the transvenous implantable cardioverter-defibrillator (TV-ICD). Patients …

Perioperative safety and early patient and device outcomes among subcutaneous versus transvenous implantable cardioverter defibrillator implantations: a …

JS Healey, AD Krahn, J Bashir, G Amit… - Annals of Internal …, 2022 - acpjournals.org
Background: Implantable cardioverter defibrillators (ICDs) improve survival in patients at risk
for cardiac arrest, but are associated with intravascular lead-related complications. The …